Nuvalent (NASDAQ:NUVL) executives highlighted ongoing regulatory milestones for the company’s lead oncology programs and discussed commercialization strategy, pipeline plans, and financial positioning during a conference fireside chat. Company focus and lead programs Chief Executive Officer Jim Porter described Nuvalent as a company built around deep chemistry and structure-based drug design expertise, with an emphasis on […]